IP Library Granted Patent US 10,973,848
Granted Patent B2
US 10,973,848 · App. 16/011,258 · Granted Apr 13, 2021

Compositions and methods for treating conditions of compromised skin barrier function

Inventors: Betty Yu (Cambridge, MA); Joseph Lomakin (Cambridge, MA); Soo-Young Kang (Cambridge, MA); Benjamin W. Adams (Somerville, MA)
Assignee: Shiseido Company, Limited
A61K31/80A61K9/0014A61K9/7015A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,973,848
App. No.
16/011,258
Granted
Apr 13, 2021
Kind
B2
Abstract

Compositions and methods useful in treating dermatological disorders are described. The methods include applying to the skin a composition comprising a reactive reinforcing component and a cross-linking component, wherein the cross-linking component facilitates a reaction to form a film in situ on the skin.

Claims (30)

1. A composition comprising a reactive reinforcing component comprising 1) a reactive constituent comprising at least one alkenyl functionalized organopolysiloxane and at least one hydride functionalized organopolysiloxane; 2) a reinforcing constituent; and (3) one or more therapeutic agent,

wherein the at least one alkenyl functionalized organopolysiloxane of the reactive reinforcing component comprises vinyl groups,

wherein the reactive reinforcing component has a molar ratio of vinyl to hydride functional groups of between about 1:35 to about 1:100, and

wherein the one or more therapeutic agent is a moisturizer, mineral oil, petroleum jelly, coal tar, anthralin, corticosteroids, fluocinonide, vitamin D3 analoges, retinoids, methotrexate, cyclosporine, a monoclonal antibody, pimecrolimus, tacrolimus, azathioprine, fluoruracil, salicylic acid, benzoyl peroxide, antibiotics, alpha-hydroxy acids, or a combination thereof,

wherein the at least one alkenyl functionalized organopolysiloxane of the reactive reinforcing component is a vinyl terminated polydimethylsiloxane;

the vinyl terminated polydimethylsiloxane of the reactive reinforcing component is of formula IIa:

wherein R 1a′ , R 3a′ , R 4a′ , R 5a′ , R 6a′ , R 8a′ , R 9a′ and R 10a′ are each independently selected from the group consisting of hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl and C 1-20 alkoxyl; and p and q are each independently an integer from between 10 and about 6000; and

the at least one hydride functionalized polysiloxane is selected from the group consisting of hydride terminated polydimethylsiloxane; polyphenyl-(dimethylhydrosiloxy)siloxane, hydride terminated; methylhydrosiloxane-phenylmethylsiloxane copolymer, hydride terminated; methylhydrosiloxane-dimethylsiloxane copolymers, trimethylsiloxy terminated; polymethylhydrosiloxanes, trimethylsiloxy terminated; polyethylhydrosiloxane, triethylsiloxane, methylhydrosiloxane-phenyloctylmethylsiloxane copolymer; methylhydrosiloxane-phenyloctylmethylsiloxane terpolymer and combinations thereof.

2. The composition of claim 1 , wherein said reactive reinforcing component has a viscosity of between about 5,000 and about 1,000,000 cSt or cP at 25° C.

3. The composition of claim 1 , wherein the at least one alkenyl functionalized organopolysiloxane of the reactive reinforcing component has a viscosity of at least about 165,000 cSt or cP at 25° C.

4. The composition of claim 1 , wherein the at least one alkenyl functionalized organopolysiloxane of the reactive reinforcing component is selected from the group consisting of vinyl terminated polydimethylsiloxane; vinyl terminated diphenyl siloxane-dimethylsiloxane copolymers; vinyl terminated polyphenylmethylsiloxane, vinylphenylmethyl terminated vinylphenylsiloxane-phenylmethylsiloxane copolymer; vinyl terminated trifluoropropylmethylsiloxane-dimethylsiloxane copolymer; vinyl terminated diethyl siloxane-dimethylsiloxane copolymer; vinylmethylsiloxane-dimethylsiloxane copolymer, trimethylsiloxy terminated; vinylmethylsiloxane-dimethylsiloxane copolymers, silanol terminated; vinylmethylsiloxane-dimethylsiloxane copolymers, vinyl terminated; vinyl gums; vinylmethylsiloxane homopolymers; vinyl T-structure polymers; monovinyl terminated polydimethylsiloxanes; vinylmethylsiloxane terpolymers; vinylmethoxysilane homopolymers and combinations thereof.

5. The composition of claim 1 , wherein the at least one alkenyl functionalized organopolysiloxane of the reactive reinforcing component has a weight percent of vinyl of between about 0.01 and about 0.1.

6. The composition of claim 1 , wherein the at least one hydride functionalized polysiloxane has a viscosity of at least about 5 cSt or cP at 25° C.

7. The composition of claim 1 , wherein the at least one hydride functionalized polysiloxane has a percent SiH content of between about 3 and about 45%.

8. The composition of claim 1 , wherein the at least one hydride functionalized polysiloxane has a SiH content of between about 0.5 and about 10 mmol/g.

9. The composition of claim 1 , wherein the at least one hydride functionalized polysiloxane is methylhydrosiloxane-dimethylsiloxane copolymers, trimethylsiloxy terminated.

10. The composition of claim 1 , wherein the reactive reinforcing component has a molar ratio of vinyl to hydride functional groups of between about 1:40 to about 1:80.

11. The composition of claim 1 , wherein the reactive reinforcing component has a molar ratio of vinyl to hydride functional groups of between about 1:50 to about 1:60.

12. The composition of claim 1 , wherein the composition is used in combination with phototherapy.

13. The composition of claim 10 , wherein the at least one alkenyl functionalized organopolysiloxane of the reactive reinforcing component is a vinyl terminated polydimethylsiloxane; and the at least one hydride functionalized polysiloxane is methylhydrosiloxane-dimethylsiloxane copolymers, trimethylsiloxy terminated.

14. The composition of claim 10 , wherein the at least one alkenyl functionalized organopolysiloxane of the reactive reinforcing component is a polymer of formula IIa:

and wherein R 1a′ , R 3a′ , R 4a′ , R 5a′ , R 6a′ , R 8a′ R 9a′ and R 10a′ are each independently C 1-20 alkyl; and p and q are each independently an integer from between 10 and 6000.

15. The composition of claim 10 , wherein the reactive reinforcing component comprises a vinyl terminated organopolysiloxane having a viscosity between about 150,000 and about 185,000 cSt or cP at 25° C., and an alkyl terminated hydride functionalized polysiloxane having a viscosity of between about 30 and about 100 cSt or cP at 25° C.

16. The composition of claim 11 , wherein the at least one alkenyl functionalized organopolysiloxane of the reactive reinforcing component is a vinyl terminated polydimethylsiloxane; and the at least one hydride functionalized polysiloxane is a methylhydrosiloxane-dimethylsiloxane copolymers, trimethylsiloxy terminated.

17. The composition of claim 11 , wherein the at least one alkenyl functionalized organopolysiloxane of the reactive reinforcing component is a polymer of formula IIa:

and

wherein R 1a′ , R 3a′ , R 4a′ , R 5a′ , R 6a′ , R 8a′ , R 9a′ and R 10a′ are each independently C 1-20 alkyl; and p and q are each independently an integer from between 10 and 6000.

18. The composition of claim 11 , wherein the reactive reinforcing component comprises a vinyl terminated organopolysiloxane having a viscosity between about 150,000 and about 185,000 cSt or cP at 25° C., and an alkyl terminated hydride functionalized polysiloxane having a viscosity of between about 30 and about 100 cSt or cP at 25° C.

19. A method for treating a dermatological disorder in a subject in need thereof, comprising: applying to the skin of the subject the composition of claim 1 , wherein the dermatological disorder is lichen simplex chronicus, cutaneous lupus, psoriasis, eczema, chronic dry skin, xeroderma, rosacea, ichthyosis, an ulcer, or any combination thereof.

20. The method of claim 19 , wherein the dermatological disorder is eczema.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2020
From: LIVING PROOF, INC.
To: OLIVO LABORATORIES, LLC
Reel/Frame 053197/0338 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2020
From: YU, BETTY; LOMAKIN, JOSEPH; KANG, SOO-YOUNG; ADAMS, BENJAMIN W.
To: LIVING PROOF, INC.
Reel/Frame 053197/0343 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2019
From: SHISEIDO AMERICAS CORPORATION
To: SHISEIDO COMPANY, LIMITED
Reel/Frame 050330/0435 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2019
From: OLIVO LABORATORIES, LLC
To: SHISEIDO AMERICAS CORPORATION
Reel/Frame 048036/0262 →
Continuity (6)
Continuation 15145918 · May 4, 2016
Division 13624483 · Sep 21, 2012
Provisional Application 61607908 · Mar 7, 2012
Provisional Application 61607905 · Mar 7, 2012
Provisional Application 61537307 · Sep 21, 2011
Related Publication 20180296591A1 · Oct 18, 2018
Cited By (3)
US 12,257,338 US 12,419,906 US 12,599,623